Tuya Inc. (TUYA)
NYSE: TUYA · Real-Time Price · USD
2.290
-0.100 (-4.18%)
At close: Aug 1, 2025, 4:00 PM
2.320
+0.030 (1.31%)
After-hours: Aug 1, 2025, 7:29 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for CTI BioPharma.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for CTI BioPharma.
Recommendation Trends
| Rating | Aug '23 | Sep '23 | Oct '23 | Nov '23 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $2.7 | Hold → Buy | Upgrades | $2.7 | +17.90% | Nov 29, 2023 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $25 → $22 | Hold → Strong Buy | Upgrades | $25 → $22 | +860.70% | May 14, 2021 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $26 | Buy | Initiates | $26 | +1,035.37% | Apr 12, 2021 |
Financial Forecast
Revenue This Year
332.91M
from 298.62M
Increased by 11.48%
Revenue Next Year
374.77M
from 332.91M
Increased by 12.57%
EPS This Year
0.12
from 0.01
Increased by 1,305.60%
EPS Next Year
0.12
from 0.12
Decreased by -2.77%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 345.9M | 404.2M | 483.5M |
| Avg | 332.9M | 374.8M | 435.8M |
| Low | 316.7M | 349.9M | 401.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 15.8% | 21.4% | 29.0% |
| Avg | 11.5% | 12.6% | 16.3% |
| Low | 6.0% | 5.1% | 7.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.14 | 0.14 | 0.17 |
| Avg | 0.12 | 0.12 | 0.15 |
| Low | 0.11 | 0.10 | 0.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1,467.5% | 11.5% | 41.2% |
| Avg | 1,305.6% | -2.8% | 24.3% |
| Low | 1,137.9% | -19.9% | 7.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.